ArticleCancer discovery2026

Preclinical Characterization and Clinical Activity of RNK08954, a Highly Selective and Orally Bioavailable KRASG12D Inhibitor.

Ling Xie et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.